During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell ...

While the initial HexaBody-CD38 clinical data is promising and showed ... resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody ... Now, the Big Pharma has determined that it won’t exercise that option, according to ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical ... resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...